Axsome Therapeutics Inc is a United States-based healthcare service provider. As a pre-clinical therapeutics developer, the company attends primarily to central nervous system disorders such as Alzheimer's. Its product portfolio consists of novel drugs like the AXS-02 (disodium zoledronate tetrahydrate), which is an oral, non-opioid therapeutic for chronic pain and the AXS-05, which is a fixed-dose combination of dextromethorphan and bupropion. The AXS-02 addresses pain in over three conditions, such as complex regional pain syndrome, knee osteoarthritis and chronic low back pain. The AXS-05 on the other hand, treats resistant depression and agitation in patients with Alzheimer's disease. Both the products have passed the preclinical, Phase 1 and Phase 2 stages of development.
| Website: | www.axsome.com |
| Email: | mjacobson@axsome.com |
| Main Phone: | +1 212 332-3241 |
| Address: | 25 Broadway |
| Address 2: | 9th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | USA |
| Postal Code: | 10004 |
| Exchange: | NSD |
| CEO: | Herriot Tabuteau |
| Employees: | 27 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 3.01 | Change $ -0.06 | Change % -1.95 | Tick N/A |
| Bid 2.95 | Bid Size 100.00 | Ask 3.38 | Ask Size 200.00 |
| Open 3.01 | High 3.11 | Low 2.96 | Prev Close 3.07 |
| Last Trade | Volume 253,770 | 52 Wk Hi 5.95 | 52 Wk Low 2.05 |
| Market Cap 89.7 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 29,813,168.00 | EPS (TTM) -1.12 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 0 |
| Number of Buys | 0 | 0 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 0 |
| Last 10 Buys | Shares |
|---|---|
| Randall E. Kaye | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| N/A | 0 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 29 | 29 | 29 | 29 |
| Low Target Price Estimate | 10 | 29 | 29 | 10 |
| Mean Target Price Estimate | 19.5 | 29 | 29 | 19.5 |
| Standard Deviation | 13.44 | 0 | 0 | 13.44 |
| Date of Most Recent Estimate | 06/07/18 | 05/25/18 | 03/08/18 | 06/07/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-05 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-29 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 96 | 2018-05-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-05-08 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
